EA NOW ACCEPTING SCIENTIFIC CONCEPTS FOR COMBOMATCH, A SUCCESSOR PRECISION MEDICINE TRIAL TO NCI-MATCH

ECOG-ACRIN Cancer Research Group, in collaboration with the National Cancer Institute (NCI) and the National Clinical Trials Network (NCTN), is developing the successor precision medicine trial to NCI-MATCH. The trial, called ComboMATCH, will concentrate on targeted drug combination signal-seeking studies supported by preclinical in vivo evidence.

The hypothesis behind this trial is that in vivo evidence, in particular PDX and cell line derived xenograft data, can be used to predict the benefit of drug combination therapy in multiple specified patient subgroups. Like MATCH, ComboMATCH is conceived as a signal-seeking study. To distinguish this trial from the original MATCH trial, this trial will focus on rational combinations of agents supported by preclinical in vivo evidence.

The trial is envisioned as having an overall Master Control document managed by EA that will coordinate separate NCTN group-specific treatment "cassettes" that each have 4-6 sub-protocols. Each cassette of 4-6 sub-protocols will be administratively managed by each of the Networks in coordination with EA.

Sub-protocol proposals will be reviewed by the ComboMATCH Agents and Genes Working Group (C-AGWG). This will consist of four members from each NCTN along with additional members with developmental therapeutics and precision oncology expertise. Accepted sub-protocols will be assembled into the different cassettes by this committee in coordination with each of the Networks.

View more information on ComboMATCH and ECOG-ACRIN's ComboMATCH RFP.

ECOG-ACRIN is soliciting ideas for possible ComboMATCH sub-protocols. Proposals may be general and are not required to be fully designed at this time. To submit a proposal, email a completed ComboMATCH Concept Sheet with any additional desired supporting material to Erin Mendelsohn at emendelsohn@ecog-acrin.org.